Radiofrequency Ablation Effective For Small Kidney Cancers
03/12/2010
Radiofrequency ablation appears to be an effective treatment for patients with small kidney cancers. These results were presented at the 2010 ASCO Genitourinary Cancers Symposium.
 
Test Available for Pre-surgical Evaluation of Ovarian Mass
03/11/2010
For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon. The test assesses the likelihood that cancer is present; when cancer is likely, surgery may best be performed by a gynecologic oncologist.
 
Obesity Linked with Worse Colon Cancer Outcomes
03/10/2010
Compared with healthy-weight patients, obese colon cancer patients have a higher risk of cancer recurrence and death. These results were published in Clinical Cancer Research.
 
Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Arimidex
03/09/2010
Among postmenopausal women with early, hormone receptor-positive breast cancer treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole), the Oncotype DX test predicts the risk of distant cancer recurrence in both node-negative and node-positive patients. These results were published in the Journal of Clinical Oncology.
 
Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer
03/09/2010
Short-term hormone therapy delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
 
Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer
03/09/2010
The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according to the results of a study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
 
PCA3 Test May Help Guide Prostate Biopsy Decisions
03/08/2010
The PCA3 urine test may help guide decisions about the need for repeat prostate biopsy in men with a negative initial biopsy but elevated PSA. These results were presented at the 2010 ASCO Genitourinary Cancer Symposium.
 
Cabazitaxel Shows Promise in Advanced Prostate Cancer
03/05/2010
Among men with metastatic, hormone refractory prostate cancer that has progressed after Taxotere® (docetaxel)-based chemotherapy, the investigational chemotherapy drug cabazitaxel may improve survival. The results of this Phase III clinical trial will be presented at the ASCO 2010 Genitourinary Cancers Symposium.
 
Benefit of Velcade on Myeloma Survival Added to Prescribing Information
03/05/2010
The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients with previously untreated multiple myeloma.
 
Cervical Vaccine Provides Little Benefit for Older Women
03/04/2010
Women over the age of 40 are not likely to benefit from a vaccine designed to prevent human papillomavirus (HPV), according to the results of a study published in the Journal of the National Cancer Institute.1 HPV has been shown to cause cervical cancer.
 

More cancer news...


© 1998-2010 www.CancerConsultants.com All Rights Reserved.

These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.